Received: 3 December 2020
Accepted: 24 May 2021
First Online: 14 June 2021
: The Ethics and Research Board of the Faculty of Pharmacy, Keio University, Tokyo, Japan, approved this study protocol (170120-1), which adhered to the principles of the Declaration of Helsinki. All participants included in the study gave written informed consent. All data were collected and handled in accordance with the relevant regulations on privacy protection in Japan.
: Not applicable.
: DEM is the developer/owner of the copyrighted MMAS diagnosed adherence assessment instrument and receives royalties. He was not involved in the data analysis. The other authors declare that they have no competing interests.